Imcyse is developing targeted immunotherapies to treat and prevent a range of autoimmune diseases. Our Type 1 Diabetes candidate has completed a phase Ib study and we are developing other molecules in Rheumatoid Arthritis, Multiple Sclerosis, Celiac disease, Neuromyelitis Optica and other diseases. The company’s unique technology interrupts the autoimmune response by specifically targeting and eliminating pathogenic immune cells involved in the destruction of the healthy organ while leaving the remainder of the immune system functioning normally.
Imotopes™, modified natural peptides, stimulate the generation of cytolytic CD4 T-cells which in turn block the autoimmune cascade. The therapy has the potential to provide long-term prevention of disease recurrence, potentially curing patients who otherwise have limited treatment options.